1-propyl-8-(1H-pyrazol-4-yl)-3,7-bis-(2-trimethylsilanyl-ethoxymethyl)-3,7-dihydro-purine-2,6-dione | 1019659-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1-propyl-8-(1H-pyrazol-4-yl)-3,7-bis-(2-trimethylsilanyl-ethoxymethyl)-3,7-dihydro-purine-2,6-dione
• 英文别名: 1-propyl-8-(1H-pyrazol-4-yl)-3,7-bis(2-trimethylsilylethoxymethyl)purine-2,6-dione
• CAS: 1019659-14-3
• 化学式: C₂₃H₄₀N₆O₄Si₂
• 分子量: 520.779
• InChiKey: YCHOPLOBVVXGKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.78
• 重原子数：
  35
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-propyl-8-(1H-pyrazol-4-yl)-3,7-bis-(2-trimethylsilanyl-ethoxymethyl)-3,7-dihydro-purine-2,6-dione 、 3-氟溴苄 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Selective, high affinity A2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

  摘要：

  A series of N-1 monosubstituted 8-pyrazolyl xanthines have been synthesized and evaluated for their affinity for the adenosine receptors (AdoRs). We have discovered two compounds 18 (CVT-7124) and 28 (CVT-6694) that display good affinity for the A(2B) AdoR (K-i = 6 nM and 7 nM, respectively) and greater selectivity for the human A(1), A(2A), and A(3) AdoRs (> 1000-, > 830-, and > 1500-fold; > 850-, > 700-, and > 1280- fold, respectively). CVT-6694 has been shown to block the release of interleukin-6 and monocyte chemotactic protein-1 from bronchial smooth muscle cells (BSMC), a process believed to be promoted by activation of A2B AdoR. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.008
• 作为产物：
  描述：

  在 palladium dihydroxide 环己烯 作用下， 以 乙醇 为溶剂， 反应 48.0h， 生成 1-propyl-8-(1H-pyrazol-4-yl)-3,7-bis-(2-trimethylsilanyl-ethoxymethyl)-3,7-dihydro-purine-2,6-dione
  参考文献：
  名称：

  Selective, high affinity A2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

  摘要：

  A series of N-1 monosubstituted 8-pyrazolyl xanthines have been synthesized and evaluated for their affinity for the adenosine receptors (AdoRs). We have discovered two compounds 18 (CVT-7124) and 28 (CVT-6694) that display good affinity for the A(2B) AdoR (K-i = 6 nM and 7 nM, respectively) and greater selectivity for the human A(1), A(2A), and A(3) AdoRs (> 1000-, > 830-, and > 1500-fold; > 850-, > 700-, and > 1280- fold, respectively). CVT-6694 has been shown to block the release of interleukin-6 and monocyte chemotactic protein-1 from bronchial smooth muscle cells (BSMC), a process believed to be promoted by activation of A2B AdoR. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.008

文献信息

• HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST
  申请人：Palle Venkata

  公开号：US20090298744A1

  公开（公告）日：2009-12-03

  Compounds of the present disclosure are fused pyrimidine compounds of formula (I), its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, as Adenosine receptor antagonists. Processes of their preparation are also described in the disclosure.

  本公开的化合物是公式（I）的融合嘧啶化合物，其互变异构体，多晶形态，立体异构体，前药，溶剂合物或其药学上可接受的盐，作为腺苷受体拮抗剂。本公开还描述了它们的制备过程。
• Heterocyclic compounds as adenosine receptor antagonist
  申请人：Advinus Therapeutics Pvt. Ltd.

  公开号：US08252797B2

  公开（公告）日：2012-08-28

  Compounds of the present disclosure are fused pyrimidine compounds of formula (I), its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, as Adenosine receptor antagonists. Processes of their preparation are also described in the disclosure.

  本公开的化合物是式（I）的融合嘧啶化合物，其互变异构体、多晶型、立体异构体、前药、溶剂化物或其药学上可接受的盐，作为腺苷受体拮抗剂。公开还描述了它们的制备过程。
• [EN] HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES COMME ANTAGONISTES DES RÉCEPTEURS ADÉNOSINIQUES
  申请人：ADVINUS THERAPEUTICS PVT LTD

  公开号：WO2009118759A3

  公开（公告）日：2009-12-10